A review on role of anti-SARS-CoV-2 monoclonal antibodies in the treatment of COVID-19
This thesis is submitted in partial fulfilment of the requirements for the degree of Bachelor of Pharmacy, 2022.
| Auteur principal: | |
|---|---|
| Autres auteurs: | |
| Format: | Thèse |
| Langue: | English |
| Publié: |
Brac University
2024
|
| Sujets: | |
| Accès en ligne: | http://hdl.handle.net/10361/24408 |
| id |
10361-24408 |
|---|---|
| record_format |
dspace |
| spelling |
10361-244082024-10-27T21:01:23Z A review on role of anti-SARS-CoV-2 monoclonal antibodies in the treatment of COVID-19 Afrin, Sadia Momtaz, Tanisha Department of Pharmacy, BRAC University Casirivimab Imdevimab Bamlanivimab SARS-CoV-2 Immunoglobulin G1 Placebo-controlled trial Covid 19--Treatment. This thesis is submitted in partial fulfilment of the requirements for the degree of Bachelor of Pharmacy, 2022. Catalogued from PDF version of thesis. Includes bibliographical references (pages 26-31). Traditional treatments and symptomatic care are still the only options for most patients as no therapeutic drug has been licensed for treating COVID-19 yet. Monoclonal antibodies generated from convalescent patients or humanized mice exposed to SARS-CoV-2 antigens were awarded emergency use authorization. An ongoing phase I, II, and III placebo-controlled trial is testing whether symptomatic adults can be treated safely and effectively. Casirivimab and imdevimab may have a therapeutic benefit in people who were seronegative when they received treatment. An IgG1 (Immunoglobulin G1) with an unaltered Fc region, Bamlanivimab was generated from the convalescent plasma of a COVID-19 patient. Patients with renal impairment, pregnancy, or breastfeeding status are not advised to alter their dosages. SARS-genomic CoV-2's organization is nearly identical to that of SARS-CoV, with the exception of a few genes for accessory proteins. Sadia Afrin B. Pharmacy 2024-10-27T09:39:25Z 2024-10-27T09:39:25Z 2022 2022-02 Thesis ID 16346051 http://hdl.handle.net/10361/24408 en BRAC University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 31 pages application/pdf Brac University |
| institution |
Brac University |
| collection |
Institutional Repository |
| language |
English |
| topic |
Casirivimab Imdevimab Bamlanivimab SARS-CoV-2 Immunoglobulin G1 Placebo-controlled trial Covid 19--Treatment. |
| spellingShingle |
Casirivimab Imdevimab Bamlanivimab SARS-CoV-2 Immunoglobulin G1 Placebo-controlled trial Covid 19--Treatment. Afrin, Sadia A review on role of anti-SARS-CoV-2 monoclonal antibodies in the treatment of COVID-19 |
| description |
This thesis is submitted in partial fulfilment of the requirements for the degree of Bachelor of Pharmacy, 2022. |
| author2 |
Momtaz, Tanisha |
| author_facet |
Momtaz, Tanisha Afrin, Sadia |
| format |
Thesis |
| author |
Afrin, Sadia |
| author_sort |
Afrin, Sadia |
| title |
A review on role of anti-SARS-CoV-2 monoclonal antibodies in the treatment of COVID-19 |
| title_short |
A review on role of anti-SARS-CoV-2 monoclonal antibodies in the treatment of COVID-19 |
| title_full |
A review on role of anti-SARS-CoV-2 monoclonal antibodies in the treatment of COVID-19 |
| title_fullStr |
A review on role of anti-SARS-CoV-2 monoclonal antibodies in the treatment of COVID-19 |
| title_full_unstemmed |
A review on role of anti-SARS-CoV-2 monoclonal antibodies in the treatment of COVID-19 |
| title_sort |
review on role of anti-sars-cov-2 monoclonal antibodies in the treatment of covid-19 |
| publisher |
Brac University |
| publishDate |
2024 |
| url |
http://hdl.handle.net/10361/24408 |
| work_keys_str_mv |
AT afrinsadia areviewonroleofantisarscov2monoclonalantibodiesinthetreatmentofcovid19 AT afrinsadia reviewonroleofantisarscov2monoclonalantibodiesinthetreatmentofcovid19 |
| _version_ |
1814307516301967360 |